GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting

GLYC 11.06.2024

Full Press ReleaseSEC FilingsOur GLYC Tweets

About Gravity Analytica

Recent News

  • 11.06.2024 - GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting
  • 10.29.2024 - Corporate Update Call
  • 10.29.2024 - GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma

Recent Filings

  • 01.13.2025 - 8-K Current report
  • 01.13.2025 - EX-99.1 EX-99.1
  • 01.13.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
PDF Version

ROCKVILLE, Md.--(BUSINESS WIRE)--Nov. 6, 2024--GlycoMimetics, Inc.(Nasdaq: GLYC) today announced that data from multiple clinical trials studying uproleselan in patients with acute myeloid leukemia (AML) have been accepted for presentation at the 66thAmerican Society of Hematology(ASH) Annual Meeting and Exposition taking place inSan Diego, California, onDecember 7-10, 2024.

ASH Annual Meeting abstracts may be accessed online atwww.hematology.org. Details ofGlycoMimeticspresentations are as follows (all times PT):

Publication Number:733Type:OralTitle:Efficacy and Safety of Uproleselan Combined with Chemotherapy Vs. Chemotherapy Alone in Relapsed/Refractory Acute Myeloid Leukemia: Findings from an International Phase 3 TrialPresenter:Daniel DeAngelo, M.D., Ph.D.SessionName:616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: New Treatment Approaches for AMLSession Date/ Presentation Time:Monday, December 9, 2024,10:30 AM–12:00 PM

Publication Number:1503Type:PosterTitle:Updated Results of a Phase I Study of Uproleselan Combined with Azacitidine and Venetoclax for the Treatment of Older or Unfit Patients with Treatment Naive Acute Myeloid LeukemiaPresenter:Brian Jonas, M.D., Ph.D.SessionName:616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster ISession Date/ Presentation Time:Saturday, December 7, 2024,5:30 PM - 7:30 PM

Publication Number:4262Type:PosterTitle:Final Results of a Phase II Study of Uproleselan Combined with Cladribine and Low-Dose Cytarabine for Patients with Treated Secondary Acute Myeloid Leukemia (ts-AML)Presenter:Caitlin Rausch, PharmD.SessionName:616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster IIISession Date/Presentation Time:Monday, December 9, 2024, 6:00 –8:00 PM

AboutGlycoMimetics, Inc.

GlycoMimeticsis a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including AML, and for inflammatory diseases. The company’s scientific approach is based on an understanding of the role that carbohydrates play in cell recognition. Its specialized chemistry platform can be used to discover small molecule drugs, known as glycomimetics, that alter carbohydrate-mediated recognition in diverse disease states, including cancers and inflammation. The company’s goal is to develop transformative therapies for diseases with high unmet medical need.GlycoMimeticsis headquartered inRockville, MDin theBioHealth Capital Region. Learn more atwww.glycomimetics.com.

Forward-Looking Statements

To the extent that statements contained herein are not descriptions of historical facts, they are forward-looking statements reflecting the current beliefs and expectations of the management ofGlycoMimetics, Inc.(“GlycoMimetics,” “we,” “us,” or “our”). Forward-looking statements include, but are not limited to, the expected presentation of clinical data for uproleselan, and any other statement containing terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “intends,” or “continue,” or the negative of these terms or other comparable terminology. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from those discussed, implied or otherwise anticipated by such statements. You are cautioned not to place undue reliance on such forward-looking statements, which are current only as of the date of this presentation. For a further description of the risks associated with forward-looking statements, as well as other risks facingGlycoMimetics, please see the risk factors described in the Company’s Annual Report on Form 10-K filed with theU.S. Securities and Exchange CommissiononMarch 27, 2024and the Company’s Quarterly Reports on Form 10-Q filed with theSEConMay 9, 2024andAugust 8, 2024, as well as other reports we file with theU.S. Securities and Exchange Commissionfrom time to time, including those factors discussed under the caption “Risk Factors” in such filings. Forward-looking statements speak only as of the date of this presentation, andGlycoMimeticsundertakes no obligation to update or revise these statements, except as may be required by law.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241106949513/en/

Investors:Argot Partners212-600-1902Glycomimetics@argotpartners.com

Source:GlycoMimetics, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com